Dose Track reminds you to inject tesamorelin each day, logs the shot with its spot on the abdomen, and counts your Egrifta vials. IGF-1 and glucose results, which the label says are checked during treatment, sit next to your doses.
The Egrifta WR label gives one dose: 1.28 mg injected under the skin of the abdomen once daily. There is no starting dose or step-up schedule. Injection sites are rotated around the abdomen, avoiding scar tissue, bruises and the navel. One 11.6 mg vial covers daily doses for 7 days in a row. Egrifta WR and Egrifta SV are not substitutable.
| Item | What the label says |
|---|---|
| Dose | 1.28 mg |
| How often | Once daily |
| Route | Subcutaneous (under the skin) |
| Where | Abdomen, rotating to different areas of the abdomen |
| Avoid | Scar tissue, bruises or the navel |
| Vial | 11.6 mg per vial; one vial provides daily doses for 7 consecutive days |
| Titration | None given; the label lists a single recommended dosage |
The label above is for Egrifta WR (11.6 mg vials). Egrifta SV is a different formulation: 1.4 mg once daily from a 2 mg single-dose vial. The label says the two are not substitutable, so add the one you actually have in Dose Track and log its dose.
Both Egrifta products are powder vials you prepare before use. An Egrifta WR vial gives daily doses for 7 days in a row; an Egrifta SV vial is one dose. In Dose Track, add the vial with the date you prepared it and set its expiry, and each daily dose comes off it. The label instructions are below.
Egrifta WR is injected under the skin (subcutaneously) into the abdomen once a day. The label says to rotate injection sites to different areas of the abdomen and not to inject into scar tissue, bruises or the navel (section 2.1).
It comes as an 11.6 mg single-patient-use vial with a multiple-dose diluent. One prepared vial provides daily doses for 7 consecutive days, and any unused solution is thrown away 7 days later (sections 2.2 and 3). The label points patients to the Instructions for Use in the Injection Box.
The Patient Information says never to share an Egrifta WR syringe or needles with anyone, even if the needle has been changed.
Each row is something worth writing down for tesamorelin, why it matters for this medicine, and what Dose Track does with it.
| What to track | Why it matters | In Dose Track |
|---|---|---|
| Daily dose | The Egrifta WR label gives one dose of 1.28 mg once daily, with no step-up schedule (2.1). | A daily reminder at your time; one tap to log. |
| Vial in use | One prepared WR vial covers 7 days in a row, and unused solution is thrown away after 7 days (2.2, 3). | Each vial keeps its prepared date and expiry, and counts down as you log. |
| Abdominal site | The label rotates sites around the abdomen and avoids scar tissue, bruises and the navel (2.1). | Each shot is logged with its abdominal site; the app suggests the next one and warns on reuse. |
| Injection site reactions | Injection site reactions were the most common side effect in the label's trials (17% vs 6% on placebo). | Record a reaction with each shot: redness, swelling, bruising, a lump or itching. |
| IGF-1 | The label says IGF-1 is monitored during treatment (5.2). | Upload a lab report; IGF-1 is read out and shown next to your doses. |
| Glucose | The label says glucose status is checked before starting and during treatment (5.4). | Glucose and HbA1c from your labs are charted against your own target range. |
In the label's 26-week placebo-controlled trials, the most common reactions were injection site reactions (17% vs 6% on placebo), joint pain (13% vs 11%), pain in the arms or legs (6% vs 5%), muscle pain (6% vs 2%) and swelling of the legs (6% vs 2%). The label also warns about higher IGF-1 levels, fluid retention, raised blood sugar and allergic reactions. There is no boxed warning.
In Dose Track you can log any of these with a severity, and use the quick picks for side effects people on peptides log most: injection-site reaction, tiredness, headache, nausea, flushing and water retention.
Egrifta WR side effects from the FDA label
The label gives no missed-dose instruction. Missed an Egrifta dose.
A day with no logged shot shows as missed in your history.
Dose Track is a tracking app, not medical advice. It records what you and your prescriber decide; it does not recommend doses. Check any dose change with your prescriber.
Sources: the FDA label for Egrifta WR (tesamorelin), version of August 3, 2026. Read on DailyMed or the guides linked above; app features checked against the current app.
All peptide trackers · All medication trackers · Supported medications · Help center